Why Is Pyridostigmine So Hard to Find? [Explained for 2026]

If you take Pyridostigmine (Mestinon) for myasthenia gravis or another condition, you may have noticed something frustrating in recent months: your pharmacy doesn't have it. You call around. Nobody has the right formulation. Your pharmacist shrugs and says they'll put in an order. Days pass.

This isn't your imagination. Pyridostigmine — particularly the 180 mg extended-release (ER) tablets — has been difficult to source at pharmacies across the United States since 2024, and the situation remains challenging heading into 2026. In this article, we'll explain exactly why this medication is so hard to find, which patients are most affected, and what your options are.

Which Pyridostigmine Formulations Are Affected?

Not all Pyridostigmine products are equally affected. The supply problems are concentrated in one specific formulation:

Pyridostigmine ER 180 mg tablets (generic Mestinon Timespan): This is the hardest formulation to find. Both Alvogen and Rising Pharmaceuticals — the two primary generic manufacturers — have reported back orders with no firm release dates since mid-2024.

Brand-name Mestinon Timespan 180 mg: Made by Bausch Health, this has remained more consistently available — but at a significantly higher price, often exceeding $800 for a 30-day supply without insurance.

Pyridostigmine IR 60 mg tablets (immediate-release): Generally available at most pharmacies, although some patients report spot shortages in their area. Generic retail pricing runs about $75–$125 for 90 tablets.

Oral solution (60 mg/5 mL syrup): Relatively available, though less commonly stocked at retail pharmacies. May need to be special-ordered.

Is There a Formal FDA Shortage for Pyridostigmine?

As of early 2026, the FDA has not formally listed Pyridostigmine Bromide on its official Drug Shortage Database. This creates a confusing gap: patients are clearly having difficulty filling prescriptions, but there's no official government acknowledgment of a nationwide shortage.

Why does this matter? Because the FDA shortage database is where manufacturers are required to report supply disruptions. Without a formal listing, there's no coordinated federal response, no mandated production increases, and no official timeline for resolution. Patients are essentially navigating a silent shortage on their own.

Why Is Pyridostigmine ER in Short Supply?

Several factors converge to make Pyridostigmine — especially the ER formulation — particularly vulnerable to supply disruptions:

1. A Small Market with Few Manufacturers

Myasthenia gravis affects an estimated 36,000 to 60,000 people in the United States — a relatively small patient population compared to chronic conditions like diabetes or hypertension. Small markets attract fewer manufacturers. For the 180 mg ER formulation, only a handful of generic makers have been in the market, leaving the supply chain fragile. When one manufacturer goes on back order, there's little slack in the system.

38,803+ patients found their medications in stock

38K+

Find Pyridostigmine In Stock Today →

2. The Extended-Release Formulation Is Complex to Manufacture

The 180 mg Timespan tablets are not just larger versions of the regular tablets. They use a specialized wax matrix that controls how the drug releases over time. This technology is more complex and more sensitive to manufacturing variability than a simple immediate-release tablet. Quality control issues, ingredient sourcing problems, or equipment downtime can halt production more easily.

3. Active Ingredients Sourced Overseas

Like many generic medications, the active pharmaceutical ingredient (API) for Pyridostigmine is largely sourced from overseas manufacturers, predominantly in India and China. Disruptions in international supply chains — whether from geopolitical tensions, quality audits, or shipping delays — can ripple through to U.S. pharmacy shelves months later.

Skip the calls, skip the stress.

Find Pyridostigmine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

4. Low Profit Margins Discourage New Market Entrants

The generic drug market for a rare-disease medication with a small patient population often generates thin profit margins. Even when a shortage exists, the economics may not be attractive enough for a new manufacturer to ramp up production quickly. This is a systemic problem across many rare-disease medications in the United States.

Who Is Most Affected by the Pyridostigmine Shortage?

Patients with myasthenia gravis who rely on the 180 mg ER tablets are hit hardest. These patients often prefer the ER formulation because it provides more consistent symptom control throughout the day with fewer doses — important for managing a condition where muscle weakness can be unpredictable and dangerous.

People who use Pyridostigmine off-label for POTS (postural orthostatic tachycardia syndrome) are also affected. POTS is increasingly common and the off-label use of Pyridostigmine has grown significantly, adding demand pressure to an already strained supply.

What Can You Do Right Now?

If you're struggling to find Pyridostigmine in stock, here are concrete steps to take today:

Call independent pharmacies: Small, independent pharmacies often use different wholesale distributors than chain pharmacies like CVS or Walgreens. This means they may have stock when the chains don't.

Ask about the IR 60 mg tablets: Talk to your doctor about temporarily switching to the immediate-release formulation while the ER version is unavailable. The IR tablets can provide similar coverage when taken on a schedule.

Try mail-order pharmacies: Express Scripts, CVS Caremark, and Amazon Pharmacy sometimes source from different wholesalers and may have stock when local pharmacies don't.

Ask for partial fills: If a pharmacy has some but not all of your supply, take what they have and check back for the rest.

Use medfinder: medfinder.com calls pharmacies near you to check which ones have your specific Pyridostigmine formulation in stock, so you don't have to make dozens of calls yourself.

Talk to Your Neurologist Before Switching Formulations

It is important to emphasize: do not simply stop taking Pyridostigmine or change your dose without talking to your doctor. Myasthenia gravis is a serious condition, and changes in your medication regimen — even switching between the IR and ER formulations — should be made in consultation with your neurologist or prescriber. An abrupt change can cause your symptoms to worsen or, in severe cases, lead to a myasthenic crisis.

The Bottom Line

Pyridostigmine ER 180 mg is genuinely difficult to find in 2026, driven by a combination of limited manufacturers, manufacturing complexity, and thin profit margins in the generic rare-disease market. If you're affected, know that you're not alone and that there are steps you can take. See our guide on how to find Pyridostigmine in stock near you for detailed, actionable tips.

For the latest availability updates, read our 2026 Pyridostigmine shortage update for patients.